Literature DB >> 11283058

Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.

S Bas1, P Muzzin, B Ninet, J E Bornand, C Scieux, T L Vischer.   

Abstract

To improve the reliability of the serodiagnosis of Chlamydia trachomatis infections, an immunoblot analysis, a microimmunofluorescence titration, and different immunoassays using synthetic peptides derived from species-specific epitopes in variable domain IV of the major outer membrane protein or recombinant antigens (heat shock protein 70 [hsp70], hsp60, hsp10, polypeptide encoded by open reading frame 3 of the plasmid [pgp3], macrophage infectivity potentiator, and a fragment of the total lipopolysaccharide) were evaluated. Because cross-reactions between chlamydial species have been reported, the microimmunofluorescence tests were also performed with Chlamydia pneumoniae and Chlamydia psittaci used as antigens, and C. pneumoniae-specific antibodies were also determined by immunoassays. Since the presence of antimicrobial antibodies must be interpreted in light of their prevalence in the general population, responses obtained with serum samples from patients with well-defined infection (i.e., with positive urethral or endocervical C. trachomatis DNA amplification) were compared to those obtained with samples from healthy blood donors. The best sensitivity (86%) with a specificity of 81% was obtained for immunoblotting results, when the number of individuals with > or =10 immunoglobulin G (IgG) and/or > or =2 IgM responses to the different C. trachomatis antigens was considered. A 13-kDa antigen was recognized by most of the samples (86% for IgG) from patients with acute urogenital infection but rarely (3%) by those from healthy blood donors (P < 0.0001). The sensitivity and specificity results obtained for serum antibodies to peptides or recombinant antigens were slightly lower than those results obtained for the number of responses to whole C. trachomatis antigens, which were 76 and 77%, respectively, when IgG responses to both recombinant hsp60 and pgp3 were considered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283058      PMCID: PMC87941          DOI: 10.1128/JCM.39.4.1368-1377.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  41 in total

1.  The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae.

Authors:  Y K Wong; J M Sueur; C H Fall; J Orfila; M E Ward
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  How useful is the Chlamydia micro-immunofluorescence (MIF) test for the gynaecologist?

Authors:  J H Wagenvoort; D Koumans; M van de Cruijs
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1999-05       Impact factor: 2.435

3.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

4.  Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera.

Authors:  M Sanchez-Campillo; L Bini; M Comanducci; R Raggiaschi; B Marzocchi; V Pallini; G Ratti
Journal:  Electrophoresis       Date:  1999-08       Impact factor: 3.535

5.  Serological investigation of Chlamydia trachomatis heat shock protein 10.

Authors:  F Betsou; J M Sueur; J Orfila
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  Antibodies to Chlamydia trachomatis heat shock proteins in women with tubal factor infertility are associated with prior infection by C. trachomatis but not by C. pneumoniae.

Authors:  K Persson; S Osser; S Birkelund; G Christiansen; H Brade
Journal:  Hum Reprod       Date:  1999-08       Impact factor: 6.918

7.  Can serology diagnose upper genital tract Chlamydia trachomatis infections? Studies on women with pelvic pain, with or without chlamydial plasmid DNA in endometrial biopsy tissue.

Authors:  M Chernesky; K Luinstra; J Sellors; J Schachter; J Moncada; O Caul; I Paul; L Mikaelian; B Toye; J Paavonen; J Mahony
Journal:  Sex Transm Dis       Date:  1998-01       Impact factor: 2.830

8.  Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease.

Authors:  D LaVerda; L N Albanese; P E Ruther; S G Morrison; R P Morrison; K A Ault; G I Byrne
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

9.  Chlamydia trachomatis antibody detection and diagnosis of reactive arthritis.

Authors:  S Bas; T L Vischer
Journal:  Br J Rheumatol       Date:  1998-10

10.  Characterization of a linear epitope on Chlamydia trachomatis serovar L2 DnaK-like protein.

Authors:  S Birkelund; B Larsen; A Holm; A G Lundemose; G Christiansen
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more
  31 in total

1.  Labsystems enzyme immunoassay for Chlamydia pneumoniae also detects Chlamydia psittaci infections.

Authors:  K Strålin; H Fredlund; P Olcén
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Chlamydia trachomatis diagnostics.

Authors:  M A Chernesky
Journal:  Sex Transm Infect       Date:  2002-08       Impact factor: 3.519

Review 3.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  Comparison of five commercial serological tests for the detection of anti-Chlamydia trachomatis antibodies.

Authors:  D Baud; L Regan; G Greub
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-28       Impact factor: 3.267

5.  Defining species-specific immunodominant B cell epitopes for molecular serology of Chlamydia species.

Authors:  K Shamsur Rahman; Erfan U Chowdhury; Anil Poudel; Anke Ruettger; Konrad Sachse; Bernhard Kaltenboeck
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

6.  A novel synthetic peptide microarray assay detects Chlamydia species-specific antibodies in animal and human sera.

Authors:  Konrad Sachse; Kh Shamsur Rahman; Christiane Schnee; Elke Müller; Madlen Peisker; Thomas Schumacher; Evelyn Schubert; Anke Ruettger; Bernhard Kaltenboeck; Ralf Ehricht
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

7.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

8.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.

Authors:  Sylvette Bas; Richard W James; Cem Gabay
Journal:  BMC Immunol       Date:  2010-09-16       Impact factor: 3.615

9.  Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection.

Authors:  Gillian S Wills; Patrick J Horner; Rosy Reynolds; Anne M Johnson; David A Muir; David W Brown; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure
Journal:  Clin Vaccine Immunol       Date:  2009-04-08

10.  Mucosal and systemic immune responses to plasmid protein pgp3 in patients with genital and ocular Chlamydia trachomatis infection.

Authors:  S Ghaem-Maghami; G Ratti; M Ghaem-Maghami; M Comanducci; P E Hay; R L Bailey; D C W Mabey; H C Whittle; M E Ward; D J M Lewis
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.